The drugs don't work - and neither does the market, when it comes to antibiotics. When sophisticated bugs that medicines used to kill within days start to fight back and...
LONDON (Reuters) - Prime Minister David Cameron called on Wednesday for global action to tackle the threat of drug-resistant superbugs and said Britain planned to take a leading role in...
By Ben Hirschler (Reuters) - U.S. drugmaker Pfizer, which failed last month in a $118 billion bid to buy AstraZeneca, said on Wednesday it had signed a deal with French...
By Ben Hirschler and Anjuli Davies LONDON (Reuters) - The world's biggest would-be drugs merger hit a wall last month but speculation about smart ways that Pfizer could yet seal...
By Ben Hirschler LONDON (Reuters) - A group of 53 leading scientists has warned the World Health Organization not to classify e-cigarettes as tobacco products, arguing that doing so would...
By Ben Hirschler and Bill Berkrot LONDON/NEW YORK (Reuters) - Pfizer abandoned its attempt to buy AstraZeneca for nearly 70 billion pounds ($118 billion) on Monday as a deadline approached...
LONDON (Reuters) - How British is AstraZeneca? With a French chief executive, Swedish chairman, 40 percent of its sales in the United States and 87 percent of its staff overseas,...
LONDON (Reuters) - Britain is ready for "hard negotiation" to ensure Pfizer sticks to specific promises on jobs and science under the U.S. drugmaker's proposed takeover of AstraZeneca, its finance...
LONDON (Reuters) - U.S. drugmaker Pfizer is under fire on both sides of the Atlantic as it weighs its next move to buy British rival AstraZeneca , which could be...
LONDON (Reuters) - Ten-year sales forecasts from AstraZeneca - a central plank of its defense against a $106 billion bid approach from Pfizer - underscore how valuing drugs is an...